RegWardenFDA facility compliance records
Recall

Class II — Macherey Nagel Gmbh & Co. Kg

Recalling firmMACHEREY-NAGEL GMBH & CO. KG.
Registered facilityMACHEREY-NAGEL GMBH & CO., KG. (the firm's only registered facility)
ClassificationClass II
StatusOngoing
ReasonThe reason for the recall is one of the test pads, for the parameter leukocytes, was missing on some of the test strips. The issue was identified by a consumer by way of a Henry Schein Inc. (HSI) customer complaint. This problem can potentially result in the possibility that the parameter leucocytes (a non-specific marker for urinary track infections and an indicator for inflammatory renal processes) is interpreted instrumentally as a false negative. The following HSI item number and lot number were affected: Urispec® 11-Way, #102-2285, LOT 65402.
ProductReagent Test Strips for Blood, Urobilinogen, Bilirubin, Protein, Nitrite, Ketones, Ascorbic Acid, Glucose, pH, Specific Gravity and Leucocytes in Urine by the Dip and Read Technique.
Quantity5,200 packages
DistributionUS Nationwide distribution in the states of CO, FL, IN, NV, TX.
Initiated2024-04-04
Classified2024-05-16
Recall numberZ-1834-2024
InitiationVoluntary: Firm initiated

Source: U.S. FDA via openFDA (opens in a new tab) (device registration & enforcement). Data as of 2026-10-06. Verify this recall record at FDA → (opens in a new tab)

Cite this record

RegWarden. “Class II recall — Macherey Nagel Gmbh & Co. Kg (Z-1834-2024).” Compiled from U.S. FDA public records (openFDA; FDA Data Dashboard). Data as of 2026-10-06. https://regwarden.com/recall/94454/

Not open yet

Alerts for MACHEREY-NAGEL GMBH & CO. KG.

Watchlist alerts will email you when FDA publishes a new recall, inspection classification, or warning letter for a facility you follow. They aren't open to the public yet — leave your email and we'll tell you when they are.

Planned

Want a one-page facility brief?

A single-page summary of this facility's registration and recall history for diligence. Not selling it yet — register interest and we'll follow up.